Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC.

Hum Mol Genet. 2006 May 15;15(10):1640-9. Epub 2006 Apr 4.

2.

The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.

Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E.

Hum Mol Genet. 2005 Oct 1;14(19):2829-37. Epub 2005 Aug 22.

3.

CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC.

Pharmacogenet Genomics. 2007 May;17(5):349-58.

4.

Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.

Kullmann S, Binner P, Rackebrandt K, Huge A, Haltern G, Lankisch M, Füth R, von Hodenberg E, Bestehorn HP, Scheffold T.

BMC Cardiovasc Disord. 2009 Oct 8;9:48. doi: 10.1186/1471-2261-9-48.

5.

Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.

Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DR Jr, Siscovick DS, Fornage M.

Atherosclerosis. 2007 Jan;190(1):26-34. Epub 2006 Mar 20.

PMID:
16545818
6.

NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities study.

Lee CR, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G, Zeldin DC.

Pharmacogenet Genomics. 2006 Dec;16(12):891-9.

7.

Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.

Fava C, Montagnana M, Danese E, Almgren P, Hedblad B, Engström G, Berglund G, Minuz P, Melander O.

Pharmacogenet Genomics. 2010 Feb;20(2):94-103. doi: 10.1097/FPC.0b013e3283349ec9.

PMID:
20065888
8.

Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans.

Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ.

Hypertension. 2011 Jan;57(1):116-22. doi: 10.1161/HYPERTENSIONAHA.110.161695. Epub 2010 Nov 22.

9.

Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC.

Clin Pharmacol Ther. 2008 Jan;83(1):52-60. Epub 2007 May 9.

10.

Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.

Corenblum MJ, Wise VE, Georgi K, Hammock BD, Doris PA, Fornage M.

Hypertension. 2008 Feb;51(2):567-73. Epub 2007 Dec 17.

11.

Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study.

Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW.

Diab Vasc Dis Res. 2008 Jun;5(2):128-34. doi: 10.3132/dvdr.2008.021.

12.

In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.

Lee JP, Yang SH, Kim DK, Lee H, Kim B, Cho JY, Yu KS, Paik JH, Kim M, Lim CS, Kim YS.

Am J Physiol Renal Physiol. 2011 Jun;300(6):F1283-90. doi: 10.1152/ajprenal.00733.2010. Epub 2011 Mar 23.

13.

Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study.

Volcik KA, Ballantyne CM, Braun MC, Coresh J, Mosley TH, Boerwinkle E.

Am J Hypertens. 2008 May;21(5):533-8. doi: 10.1038/ajh.2007.81. Epub 2008 Feb 21.

14.

Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population.

Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC, Wang DW.

Pharmacogenet Genomics. 2008 Jan;18(1):45-51. doi: 10.1097/FPC.0b013e3282f313e8.

15.

Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans.

Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Müller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M.

Stroke. 2008 May;39(5):1593-6. doi: 10.1161/STROKEAHA.107.502179. Epub 2008 Mar 6.

17.
18.

Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study.

Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT, Boerwinkle E.

Atherosclerosis. 2008 Feb;196(2):926-30. Epub 2007 Mar 9.

PMID:
17350020
20.

Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.

Lee J, Dahl M, Grande P, Tybjaerg-Hansen A, Nordestgaard BG.

Stroke. 2010 Jan;41(1):27-33. doi: 10.1161/STROKEAHA.109.567768. Epub 2009 Nov 25.

Supplemental Content

Support Center